BPC-157 in the US: Purity, Batch Certificates and What to Check

BPC-157 is a synthetic 15-residue peptide, sequence GEPPPGKPADDAGLV, corresponding to a partial sequence of BPC ("Body Protection Compound"), a roughly 40-residue protein identified in human gastric juice. The fragment was characterized in the early 1990s by the research group of Predrag Sikiric at the University of Zagreb, in the context of what that group called the stomach stress-organoprotection hypothesis.[1]

It is supplied as a lyophilized powder, most commonly as the acetate salt. The arginate salt appears occasionally in research supply. The two differ in handling and solubility, not in the underlying peptide sequence.

Research Material

The sequence is short, unmodified and entirely composed of standard proteinogenic residues, with no cyclization, no lipidation and no non-natural amino acids. That is worth knowing when you evaluate a certificate: BPC-157 is a straightforward synthesis, so a genuinely low purity figure points at a manufacturing or storage problem rather than an inherently difficult target.

Amino Acid Sequence

Chemical Structure

The literature is large by research-peptide standards and concentrated in a small number of groups. These are the directions that have actually been published, stated as what was observed in which model:

• ·Tendon models. Staresinic et al. (2003) reported accelerated healing of transected rat Achilles tendon and stimulation of tendocyte growth in vitro.[2] Chang et al. (2011) reported effects on tendon outgrowth, cell survival and cell migration in tendon fibroblast assays.[3]
• ·Wound and angiogenesis models. Huang et al. (2015) examined alkali-burn wound healing in vivo, with in-vitro evidence of proliferation, migration and angiogenesis.[4]
• ·Vascular signaling. Hsieh et al. (2020) characterized modulation of vasomotor tone via the Src, Caveolin-1 and eNOS pathway in experimental vascular preparations.[5]
• ·Gastrointestinal cytoprotection. The original 1993 framing of the BPC family concerned gastric mucosal protection, and remains the oldest continuous thread in the literature.[1]

There are no completed, published, randomized human efficacy trials of BPC-157. Every finding above comes from cell culture or animal models. A small oral formulation (PL-14736) entered early clinical work for inflammatory bowel disease and did not produce a published pivotal dataset. There is no established human dose, no human safety record of any size, and no approved indication in any jurisdiction.

A large preclinical literature concentrated in one research group is a reason to take a compound seriously as a research subject. It is not a substitute for human data, and any supplier presenting it as one is misrepresenting what has been published.

On 23 and 24 July 2026 the FDA's Pharmacy Compounding Advisory Committee reviewed BPC-157 for inclusion on the Section 503A Bulk Drug Substances List, alongside BPC-157, KPV, TB-500, MOTS-c, Epitalon and Semax. FDA staff had recommended against inclusion for every substance under review, citing insufficient characterization, little or no human effectiveness evidence, and inadequate human safety data. The committee voted in favor anyway. The vote was 8 in favor, 6 against, 1 abstention.

That result was widely reported as a regulatory shift. It is worth being precise about what it does:

• ·It is non-binding. The committee advises, it does not decide. No final FDA determination has been issued and none of the six peptides appears in 21 CFR 216.23.
• ·It requires a further step. Addition to the 503A Bulks List requires formal action by the Secretary of Health and Human Services, which had not occurred as of publication.
• ·It does not make the compound an FDA-approved drug, and it establishes nothing about efficacy.
• ·It does not legitimize research-chemical retail. A compounding-list decision concerns licensed pharmacists preparing patient-specific prescriptions under Section 503A, which is a different channel entirely from research material sold in vials.

Purity and content answer two different questions, and a listing that reports only the first has told you half the story. Purity is the fraction of what is in the vial that is the stated compound. Measured content is how much of it is there against the labeled amount. A vial can be 99.5% pure and hold 6 mg where the label says 10 mg, and a purity figure alone will never reveal that.

Mass-spectrometry identity confirmation closes the third gap: it establishes that the pure material is the right molecule. For a 15-residue peptide with a distinctive mass near 1419.5 Da, that is a cheap check for a laboratory to run and an expensive one to fake.

Every Eppix BPC-157 lot is tested by Janoshik Analytical and the certificate is published before the lot goes on sale, verifiable on the laboratory's own database rather than as a PDF hosted by the seller. The certificate below is the current published lot. Use the strength buttons to move between strengths.

Published Certificate

Select strength

10mg12mg20mg

Batch

BPC-CA-25L-01

Purity (HPLC)

99.765%

Measured content

10.98 mglabeled 10 mg

Laboratory

Janoshik

Verify on the lab’s own databaseAll published certificates

If you read nothing else on a certificate, read these four lines. Our longer walkthrough is in how to verify a peptide COA, and the failure modes are catalogued in how to spot a fake COA.

• ·Batch number, and it matches the number on the vial you are being sold, not a different lot from six months ago.
• ·Named testing laboratory, with a verification path on that laboratory's own site.
• ·Identity by MS, not purity alone.
• ·Measured content against labeled content, reported as a number rather than described as "verified".

Eppix ships domestically within the United States by FedEx, typically one to three business days across the country, with free shipping over $200 USD. Card and PayPal checkout are both available, and mix-and-match pricing applies at 5 and 10 vials across the catalog rather than per product.

Researchers working tissue-repair models frequently pair BPC-157 with TB-500; the two are compared directly in BPC-157 vs TB-500. The full literature overview, separate from this sourcing guide, is at BPC-157: a research literature overview.

Available at Eppix Labs

BPC-157

10mg · 12mg · 20mg

Every batch tested by an independent laboratory, with the certificate published before sale.

From $49.99 USDIn stock